Card image cap
MindMaze receives $105 million funding for neurotherapeutics R&D

Hinduja group-backed neurotherapeutics research company MindMaze has secured a $105 million financing round to accelerate its global commercial growth plans, supercharge ongoing research and development and consolidate the clinical development pipeline of its industry-defining digital therapeutic solutions for a wide spectrum of neurological diseases.

Content by Future Medicine

Disclaimer :
The author(s)' thoughts and opinions in this article are their own and do not necessarily reflect DocMode's viewpoint. The article is in no way created or edited by DocMode.


Supported by Koye Pharmaceuticals

Submit a Comment